Extensive-stage Small Cell Lung Cancer (ES-SCLC) Clinical Trials

13 recruitingLast updated: June 17, 2026

There are 13 actively recruiting extensive-stage small cell lung cancer (es-sclc) clinical trials across 43 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include Shanghai, China, Roma, Italy, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Extensive-stage Small Cell Lung Cancer (ES-SCLC) Trials at a Glance

13 actively recruiting trials for extensive-stage small cell lung cancer (es-sclc) are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Shanghai, Roma, and Houston. Lead sponsors running extensive-stage small cell lung cancer (es-sclc) studies include Anhui Provincial Cancer Hospital, Bindu R Potugari, and Akeso.

Browse extensive-stage small cell lung cancer (es-sclc) trials by phase

Treatments under study

About Extensive-stage Small Cell Lung Cancer (ES-SCLC) Clinical Trials

Looking for clinical trials for Extensive-stage Small Cell Lung Cancer (ES-SCLC)? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Extensive-stage Small Cell Lung Cancer (ES-SCLC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 1Phase 2

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Novartis Pharmaceuticals80 enrolled3 locationsNCT07564401
Recruiting
Phase 3

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Extensive-stage Small Cell Lung Cancer (ES-SCLC)Small Cell Lung Cancer ( SCLC )
Boehringer Ingelheim670 enrolled236 locationsNCT07472517
Recruiting
Phase 3

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences695 enrolled210 locationsNCT06801834
Recruiting
Phase 2

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer (ES-SCLC)Small Cell Lung Cancer ( SCLC )
Bindu R Potugari35 enrolled1 locationNCT07339059
Recruiting
Phase 1

Iadademstat + SBRT With Atezo in ES-SCLC

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Yale University15 enrolled1 locationNCT07113691
Recruiting
Phase 2

Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Chongqing University Cancer Hospital36 enrolled1 locationNCT07425795
Recruiting
Phase 1

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Breast CancerColorectal, CancerOvarian Cancer+6 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Phase 2

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

Lung NeoplasmsThoracic NeoplasmsLung Diseases+1 more
Shanghai Pulmonary Hospital, Shanghai, China15 enrolled1 locationNCT06758700
Recruiting
Phase 2

A Study of Ivonescimab in First-Line ES-SCLC

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Akeso180 enrolled3 locationsNCT07245446
Recruiting
Phase 2

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Anhui Provincial Cancer Hospital56 enrolled1 locationNCT06838208
Recruiting

Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Shanghai Chest Hospital of Shanghai Jiao Tong University38 enrolled1 locationNCT07070011
Recruiting
Phase 2

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gruppo Oncologico Italiano di Ricerca Clinica142 enrolled25 locationsNCT06663098
Recruiting
Not Applicable

Second-line Immunotherapy for ES-SCLC

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Tianjin Medical University Cancer Institute and Hospital30 enrolled1 locationNCT06853678